|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.48 USD | +1.60% |
|
+8.92% | -1.90% |
| May. 10 | HC Wainwright Adjusts Catalyst Pharmaceuticals' Price Target to $26 From $24, Keeps Buy Rating | MT |
| May. 09 | Transcript : Catalyst Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Catalyst Pharmaceuticals, Inc. continued to forecast full year 2022 total revenues to be in the range of between $195 million and $205 million, representing a 38% - 45% increase in total revenues as compared to 2021.
| 1st Jan change | Capi. | |
|---|---|---|
| -1.90% | 1.92B | |
| -2.47% | 89.37B | |
| +2.76% | 40.65B | |
| -12.59% | 32.81B | |
| +52.41% | 25B | |
| -17.34% | 15.29B | |
| -42.45% | 11.61B | |
| -10.48% | 11.49B | |
| +6.14% | 8.98B | |
| -7.72% | 8.23B |
CATALYST PHARMACEUTICALS, INC. 
